Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

Figures & data

Table I. Baseline characteristics of patients with PIK3CA-mutated CRC comparing aspirin use to non-use.

	Total	Aspirin use		Aspirin non-use		p-Value
Number	185	49		136
Median age (years)	72	74		70		0.009
Median follow-up (months)	54	53		54		0.10
Cancer center						0.40
RMH	112	27	55%	85	63%
Moffitt	73	22	45%	51	38%
Primary site						0.006
Right-sided	107	20	41%	87	64%
Left-sided	77	29	59%	48	35%
Unknown	1	0	0%	1	1%
AJCC Stage						0.52
1	8	2	4%	6	4%
2	66	16	33%	50	37%
3	67	22	45%	45	33%
4	44	9	18%	35	26%

Figure 1. Overall survival for patients with PIK3CA mutated CRC: Aspirin use versus non-use across all stages.

Figure 2. Cancer-specific survival for patients with PIK3CA mutated CRC: Aspirin use versus non-use across all stages.

Table II. Univariate and multivariate overall and cancer-specific survival analyses for patients with PIK3CA mutated CRC.

	Overall survival
	Univariate			Multivariate
	HR	95% CI	p-Value	HR	95% CI	p-Value
Aspirin use	0.96	0.58, 1.57	0.86	0.95	0.55, 1.63	0.85
Age (decades)	1.37	1.10, 1.71	0.006	1.41	1.10, 1.81	0.009
Stage
1/2	1			1
3	2.16	1.18, 3.93	0.012	2.33	1.26, 4.31	0.007
4	4.31	2.38, 7.80	< 0.001	4.65	2.53, 8.55	< 0.001
Cancer center (Moffitt referent)	1.62	0.99, 2.66	0.055	1.32	0.79, 2.21	0.30
Primary site (right referent)	0.72	0.45, 1.14	0.16	0.64	0.39, 1.05	0.08

	Cancer-specific survival
	Univariate			Multivariate
	HR	95% CI	p-Value	HR	95% CI	p-Value
Aspirin use	0.60	0.34, 1.16	0.14	0.66	0.31, 1.38	0.27
Age (decades)	1.09	0.85, 1.41	0.51	1.06	0.77, 1.45	0.72
Stage
1/2	1			1
3	2.93	1.12, 7.65	0.028	3.08	1.17, 8.10	0.023
4	11.83	4.92, 28.47	< 0.001	12.46	5.14, 30.22	< 0.001
Cancer center (Moffitt referent)	1.62	0.88, 2.98	0.12	1.33	0.69, 2.53	0.39
Primary site (right referent)	0.75	0.42, 1.32	0.32	0.62	0.35, 1.13	0.12

Table III. Overall, cancer-specific and recurrence-free survival for patients with PIK3CA-mutated CRC – Aspirin use versus non-use (per stage).

	Overall survival			Cancer-specific survival			Recurrence-free survival
	HR	95% CI	p-Value	HR	95% CI	p-Value	HR	95% CI	p-Value
Stage 2 (n = 66)	2.41	0.94, 9.16	0.06	1.79	0.28, 13.7	0.49	1.34	0.22, 5.81	0.67
Stage 3 (n = 67)	1.14	0.54, 2.50	0.74	0.87	0.28, 2.71	0.82	0.85	0.30, 2.40	0.76
Stage 4 (n = 44)	0.40	0.21, 1.00	0.06	0.40	0.21, 1.00	0.06	–	–	–